ReviewACS omega2026
Progress in Protein Nanoparticle Vaccines for Human Viral Diseases.
Review in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the development of antiviral vaccines, insufficient immunogenicity and limited cross-protective efficacy against rapidly evolving viruses remain as major challenges. Protein nanoparticle vaccine platforms have emerged as a promising strategy because of their capacity for multivalent antigen presentation, structural stability, and enhanced immunogenicity. Both naturally occurring and computationally designed protein nanoparticles, including ferritin, lumazine synthase, E2p, I53-50, I301, and mi3, have been widely investigated for the presentation of diverse viral antigens. In this review, we summarize recent advances in protein nanoparticle vaccines for major human viral diseases, with emphasis on how nanoparticle geometry, assembly architecture, and antigen-display strategies influence immunogenicity and broad-spectrum immune responses. We further discuss recent progress in mosaic antigen display, germline-targeting immunogens, and clinically translated nanoparticle vaccine platforms together with current challenges and future directions in scaffold engineering and vaccine design. Protein nanoparticle platforms provide a versatile foundation for structure-guided antiviral-vaccine development.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.